We conducted a multicenter prospective study to clarify the efficacy and safety of surgery and imatinib for liver oligometastasis of gastrointestinal stromal tumors. Eligible gastrointestinal stromal tumor patients were enrolled in the surgery trial or the imatinib trial. Primary endpoints were recurrence-free survival and progression-free survival, respectively. The trials were prematurely terminated due to amendment of guidelines for adjuvant imatinib therapy and low patient accrual. In the surgery trial, all the six patients showed hepatic recurrence: median recurrence-free survival was 145 days (range: 62-1366 days). Of the five patients receiving salvage imatinib therapy, two showed progressive disease although no death was observed. Of the five patients enrolled in the imatinib trial, one died of pneumonia after progressive disease, and four had not shown progressive disease as of last visit. The results suggest that liver oligometastasis of gastrointestinal stromal tumor may not be controllable by surgery alone and require concomitant imatinib therapy.
Introduction
Liver metastasis is the most common recurrence in patients with gastrointestinal stromal tumors (GISTs). Surgical resection has long been the lone treatment expected to have survival benefits for patients with GIST liver metastasis (GLM). However, molecular targeted therapy with imatinib has become the new standard therapy for GLM after the emergence of clinical studies reporting that the median survival time (MST) in advanced GIST patients who have undergone imatinib therapy is 5 years or longer (1, 2) .
Despite its high clinical efficacy, imatinib has some limitations, including disease progression in the late phase of treatment (imatinib secondary resistance) and an absolute necessity to continue medication (lifelong use of imatinib). These limitations of imatinib therapy have sparked the re-evaluation of the surgical resection of GLM. Surgical studies in the pre-imatinib era have suggested that liver resection in selected patients, e.g. patients with long diseasefree intervals, results in good survival after the metastasectomy (3, 4) . In addition, advances in surgical devices and techniques have made hepatectomy safer and less invasive than before. Thus, the clinical guidelines for GIST in Japan (5) recommend imatinib therapy as the standard therapy for GLM, although still retaining surgical resection as an optional treatment for GLM. However, all the previous studies of the surgery for GLM were retrospective (3, 4, (6) (7) (8) , and no survival data for the overall population were available. Moreover, many of those studies included surgery for the metastasis of non-GIST sarcomas. The lack of robust clinical evidence has fueled controversy regarding the recommendation of surgical resection to GLM patients in Japan.
To obtain solid evidence on the surgery for GLM, the Japanese Study Group on GIST launched a multicenter prospective study in 2008. We herein report the results of the study.
Patients and methods

Study design
The multicenter prospective study was composed of two phase II trials: the surgery and the imatinib trials. GLM patient recruitment from 104 medical institutions in Japan was started in October 2008. Patients who gave informed consent were enrolled in either trial according to patient preference.
The two trials had the same eligibility criteria. Eligible were histologically KIT-positive GIST patients, who presented with liver metastasis having three or less deposits. Other eligibility criteria included diagnosis of the liver metastasis as being resectable by preoperative imaging examination, no extrahepatic metastasis, no prior history of GIST recurrence, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients positive for hepatitis B surface antigen and those who had a history of previous treatment with tyrosine kinase inhibitors (TKIs) were excluded.
The study protocols were approved by the institutional review boards of the participating medical institutions. Both trials were registered at ClinicalTrials.gov as NCT00769782 (surgery trial) and NCT00764595 (imatinib trial).
Treatment
Patients in the surgery trial underwent GLM resection within 28 days after enrollment. The resection ranges and procedures were not specified if they assured complete resection (R0). The patients were regularly followed up without prescribing imatinib.
Patients in the imatinib trial started imatinib therapy within 28 days after enrollment and continued the therapy until progressive disease (PD) or intolerance to the treatment was noted. The dosage of imatinib mesylate was 400 mg daily and could be reduced when severe treatment-related toxicities were reported.
Endpoint and assessment
The primary endpoint was recurrence-free survival (RFS) in the surgery trial and progression-free survival (PFS) in the imatinib trial. The secondary endpoints included overall survival (OS), R0 resection rate, and surgical morbidity in the surgery trial, and OS, tumor response, and treatment-related adverse events (AEs) in the imatinib trial. Imatinib failure-free survival (IFFS), which is the time from metastasectomy to death from any cause or objectively determined PD when imatinib therapy was used as the secondary treatment for recurrence, was also analyzed in the surgery trial.
Computed tomography (CT) scans with contrast enhancement were performed at 8-week intervals in the first year and at threemonth intervals thereafter in both trials. Tumor response was assessed according to the Response Evaluation Criteria in Solid Tumors guidelines, version 1.0. In this study, focal progression, i.e. nodular regrowth that emerged in degenerated lesions and showed a significant increase in contrast enhancement on CT, was also determined as PD. The cutoff date for the analyses was May 28, 2014.
Statistical analysis
The cumulative RFS, PFS, IFFS and OS rates were estimated using the Kaplan-Meier method. The confidence interval approach was used to calculate the minimum sample size required for each trial. We assumed that the expected RFS and the minimum bound in the surgery trial were 40 and 24 months, respectively, and the expected PFS and the minimum bound in the imatinib trial were 30 and 20 months, respectively. By applying Fleming's single-stage method at alpha = 0.05 (one-sided) with 80% power, we determined that the required sample sizes for the surgery and imatinib trials were 35 and 33 patients, respectively. Finally, the target sample sizes were set to 44 patients in the surgery trial and 37 patients in the imatinib trial, considering dropout.
Results
Patient accrual
Enrollment was discontinued in August 2011 due to the amendment of the recommended guidelines for adjuvant imatinib therapy and the low patient accrual. Six and five eligible patients were finally enrolled in the surgery and the imatinib trials, respectively.
Surgery
We summarize the surgical outcomes for the six patients enrolled in the surgery trial in Table 1 . All the six patients underwent macroscopic and microscopic complete resections (R0 resection). The selected procedures were partial resection in three patients, segmentectomy or subsegmentectomy in two, and segmentectomy plus partial resection in one. Median operative blood loss was 468 mL (range: 169-2520 mL). One patient underwent blood transfusion during surgery. Although grade-3 alanine aminotransferase and/or aspartate aminotransferase were detected in three patients, no patient required surgical, endoscopic or radiological intervention. Median postoperative hospital stay of the six patients was 13 days (range: 11-18 days).
Imatinib therapy
We summarize the results of the five patients enrolled in the imatinib trial in Table 1 . Complete response (CR) was noted in one patient, partial response (PR) in two patients and stable disease (SD) in two patients.
All the five patients had treatment-related AEs; grade-3 AEs were neutropenia in two patients and fracture of the lower limb, shoulder arthritis and aspiration in one patient each. One patient who showed CR discontinued imatinib therapy 15 months after enrollment, whereas the remaining four continued imatinib therapy until their last visits.
Prognosis
All the six patients in the surgery trial showed hepatic recurrence. A 3-year RFS was 16.7% and median RFS was 145 days (range: 62-1366 days) (Fig. 1A) .
Selected salvage therapies for the hepatic recurrence were imatinib therapy in four patients, proton therapy in one, and metastasectomy (re-resection) in one. The metastasectomized patient suffered from recurrence again and received imatinib therapy thereafter. Of the five patients who used imatinib as second-or third-line therapy, two showed PD during the salvage imatinib therapy (imatinib secondary resistance) on postoperative days 349 and 712. A 3-year IFFS was 66.7%. All the six patients were alive until the cutoff date (Fig. 1A) .
In the imatinib trial, an 81-year-old female patient showed progression 489 days after imatinib therapy initiation and died of pneumonia 692 days after the diagnosis of PD. The remaining four were alive and showed no signs of PD at the cutoff date. A 3-year PFS was 75%, and median PFS was not reached during the study period (Fig. 1B) . g ANP ANP, alive with no disease progression; AWD, alive with disease; CR, complete response; DOD, death due to other disease; F, female; M, male; Op, operative diagnosis; Preop, preoperative diagnosis; PFS, progression-free survival; PR, partial response; R0, no residual tumor; RFS, recurrence-free survival; SD, stable disease. 
DISCUSSION
We have presented herein the results of our multicenter prospective study of the treatment selection for liver oligometastasis of GIST. Despite expectations of high quality evidence, the present study was discontinued prior to full enrollment.
In the surgery trial, RFS was the primary endpoint, and the patients were followed up without postoperative imatinib therapy in order to clarify the disease-controlling power of surgery per se. At the time of initiation of this study, clinical guidelines did not recommend adjuvant imatinib therapy after R0 resection of GISTs because the impact on patient survival was still unclear. The SSGXVIII study, a randomized phase III trial conducted in Europe (9), however, showed that OS was significantly shorter in patients receiving adjuvant imatinib therapy for 1 year than in those for 3 years. That result suggested that the noadjuvant strategy may have potential adverse effects on patient survival. In addition to the new evidence, actual patient enrollment was much lower than expected. For these reasons, the Independent Data Monitoring Committee of this study advised early termination.
Despite the early termination, the present study provided valuable data that helped us make treatment decisions for patients with resectable GLM. Early case studies revealed a high incidence of rerecurrence in patients, who underwent surgical resection of GLM, but were unable to offer any data on RFS due to their retrospective nature. The present study showed that all the six patients suffered from hepatic recurrence. In addition, the strict follow-up protocol of this study enabled us to determine that the median RFS was as short as 145 days. On the basis of investigators' consensus, the minimum bound of clinically required RFS was set at 24 months in the surgery trial of this study. Only one patient met the minimum bound of RFS, strongly suggesting that GLM was uncontrollable by surgery alone and needed postoperative imatinib therapy.
Secondary resistance is essentially inevitable in patients undergoing imatinib therapy (10) , and median PFS is known to be as low as 2-3 years. The specific, unfavorable nature of imatinib has led to the formulation of a hypothesis that the surgical resection of GLM, sparing the highly effective but time-restricted TKI, might afford longer OS than imatinib monotherapy because patients would still be able to undergo imatinib therapy for re-recurrence after the metastasectomy. The present study, however, did not corroborate the hypothesis. Five of the six patients enrolled in the surgery trial eventually underwent imatinib therapy after confirmation of recurrence. Although the patients showed significant response to the salvage imatinib therapy, imatinib secondary resistance was noted in two patients during the study period. On the other hand, the disease-control time by imatinib monotherapy was relatively long in this study. Median PFS in the imatinib trial was not reached until the cutoff date. Two large-scale studies of advanced GIST patients indicated that initial tumor volumes influenced patient survival in imatinib therapy (1, 11) . The prognosis of patients who underwent imatinib therapy for resectable GLM may be better than expected.
From the point of view of prognosis, this study did not yield any evidence supporting the preference for surgical resection in patients with resectable GLM. The indication of surgical resection should be limited to genotypically imatinib-resistant tumors, such as wild-type GIST or platelet-derived growth factor alpha receptor-mutated GIST.
